Lyell Immunopharma, Inc.
LYEL
$17.92
-$1.10-5.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 247.22M | 319.62M | 276.79M | 301.18M | 370.53M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 13.72M | 8.58M | 5.42M | 8.00M | 9.07M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 260.94M | 328.20M | 282.21M | 309.18M | 379.59M |
|
|
|||||
| Total Current Assets | 260.94M | 328.20M | 282.21M | 309.18M | 379.59M |
| Net Property, Plant & Equipment | 53.64M | 56.63M | 60.07M | 67.77M | 72.94M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.47M | 4.13M | 4.11M | 4.91M | 6.31M |
| Total Assets | 340.05M | 407.97M | 385.45M | 429.80M | 490.86M |
|
|
|||||
| Total Accounts Payable | 2.89M | 2.57M | 3.38M | 3.73M | 5.37M |
| Total Accrued Expenses | 20.94M | 29.31M | 19.49M | 22.93M | 29.37M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 9.07M | -- | 8.51M | 8.24M | 7.97M |
| Total Finance Division Other Current Liabilities | 16.51M | -- | 5.53M | 6.39M | 11.08M |
| Total Other Current Liabilities | 16.51M | -- | 5.53M | 6.39M | 11.08M |
| Total Current Liabilities | 49.41M | 31.88M | 36.90M | 41.29M | 53.79M |
|
|
|||||
| Total Current Liabilities | 49.41M | 31.88M | 36.90M | 41.29M | 53.79M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 41.92M | 44.29M | 46.60M | 48.85M | 50.99M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 517.00K | 2.68M | 3.03M | 3.14M | 3.25M |
| Total Liabilities | 91.85M | 78.84M | 86.53M | 93.28M | 108.04M |
|
|
|||||
| Common Stock & APIC | 1.87B | 1.81B | 1.74B | 1.73B | 1.73B |
| Retained Earnings | -1.62B | -1.48B | -1.44B | -1.40B | -1.35B |
| Treasury Stock & Other | 242.00K | 201.00K | 57.00K | 158.00K | 291.00K |
| Total Common Equity | 248.20M | 329.12M | 298.92M | 336.52M | 382.82M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 248.20M | 329.12M | 298.92M | 336.52M | 382.82M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 248.20M | 329.12M | 298.92M | 336.52M | 382.82M |
|
|
|||||